Dihydrofolate Reductase Antikörper

Produktnummer ABIN1387277

Produktdetails anti-Dihydrofolate Reductase Antikörper

Target: Dihydrofolate Reductase (DHFR)

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser Dihydrofolate Reductase Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Flow Cytometry (FACS), Immunofluorescence (Paraffin-embedded Sections) (IF (p))

Aufreinigung: purified by Protein A and peptide affinity chromatography

Immunogen: KLH conjugated synthetic peptide derived from human DHFR

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: WB (1:100-500),IHC-P (1:100-500),FACS (1:50-200),IF (p) (1:50-200)

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 µg/µL

Buffer: Aqueous buffered solution containing 100 µg/mL BSA, 50 % glycerol and 0.09 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Store at -20 °C for 12 months

Haltbarkeit: 12 months

Details zu Dihydrofolate Reductase

Target: Dihydrofolate Reductase (DHFR)

Andere Bezeichnung: DHFR (DHFR Produkte)

Hintergrund: DHFR catalyzes the NADPH-dependent reduction of dihydrofolate to tetrahydrofolate, and is a crucial enzyme for the synthesis of purines, pyrimidines and some amino acids. Inhibition of the activity of this enzyme leads to arrest of DNA synthesis and cell death. Gene expression of methotrexate (MTX)-resistant variants of DHFR in normal hematopoietic cells is a potential strategy to permit administration of larger doses of MTX by alleviating drug toxicity in normal cells and tissues that are drug sensitive.

Molekulargewicht: 21kDa

Gen-ID: 1719

HGNC: 0

Pathways: Mitotic G1-G1/S Phases